Doxorubicin Injection

Doxorubicin pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Share Now

Name Doxorubicin Injection

Description

Doxorubicin pegylated liposomal is indicated:

– As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.

– For treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.

– In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

– For treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.

Doxorubicin pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Active Ingredient

Doxorubicin

Indication

Adjuvant Breast Cancer

Doxorubicin HCl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer

Doxorubicin HCl is indicated for the treatment of

Strengths

2mg/5,25&100ml